1674 related articles for article (PubMed ID: 17895328)
1. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
2. Costs of managing anemia with erythropoiesis-stimulating agents during hemodialysis: a time and motion study.
Schiller B; Doss S; DE Cock E; Del Aguila MA; Nissenson AR
Hemodial Int; 2008 Oct; 12(4):441-9. PubMed ID: 19090867
[TBL] [Abstract][Full Text] [Related]
3. Characterizing hospitalizations of end-stage renal disease patients on dialysis and inpatient utilization of erythropoiesis-stimulating agent therapy.
Brophy DF; Daniel G; Gitlin M; Mayne TJ
Ann Pharmacother; 2010 Jan; 44(1):43-9. PubMed ID: 20028955
[TBL] [Abstract][Full Text] [Related]
4. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
[TBL] [Abstract][Full Text] [Related]
5. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
6. Healthcare expenditure and resource utilization in patients with anaemia and chronic kidney disease: a retrospective claims database analysis.
Wish J; Schulman K; Law A; Nassar G
Kidney Blood Press Res; 2009; 32(2):110-8. PubMed ID: 19372704
[TBL] [Abstract][Full Text] [Related]
7. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
[TBL] [Abstract][Full Text] [Related]
8. Medical costs of untreated anemia in elderly patients with predialysis chronic kidney disease.
Lefebvre P; Duh MS; Buteau S; Bookhart B; Mody SH
J Am Soc Nephrol; 2006 Dec; 17(12):3497-502. PubMed ID: 17082245
[TBL] [Abstract][Full Text] [Related]
9. Utilization and cost comparison of erythropoiesis-stimulating agents in inpatient and outpatient hospital settings.
Lafeuille MH; Bailey RA; Vekeman F; Scott McKenzie R; Lefebvre P
J Med Econ; 2012; 15(2):352-60. PubMed ID: 22168787
[TBL] [Abstract][Full Text] [Related]
10. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
[TBL] [Abstract][Full Text] [Related]
11. Cost comparison of peritoneal dialysis versus hemodialysis in end-stage renal disease.
Berger A; Edelsberg J; Inglese GW; Bhattacharyya SK; Oster G
Am J Manag Care; 2009 Aug; 15(8):509-18. PubMed ID: 19670954
[TBL] [Abstract][Full Text] [Related]
12. A naturalistic comparison of amoxicillin/clavulanate extended release versus immediate release in the treatment of acute bacterial sinusitis in adults: A retrospective data analysis.
Jackson J; Fernandes AW; Nelson W
Clin Ther; 2006 Sep; 28(9):1462-71. PubMed ID: 17062318
[TBL] [Abstract][Full Text] [Related]
13. Drug utilization and cost for erythropoiesis-stimulating agents in a long-term care resident population with chronic kidney disease.
Lafeuille MH; Bailey RA; Vekeman F; Kilpatrick BS; Senbetta M; Piech CT; Lefebvre P
Consult Pharm; 2010 Aug; 25(8):493-500. PubMed ID: 20736158
[TBL] [Abstract][Full Text] [Related]
14. Predictors of ESA use in the non-dialysis chronic kidney disease population with anemia.
Collins AJ; Guo H; Gilbertson DT; Bradbury BD
Nephron Clin Pract; 2009; 111(2):c141-8. PubMed ID: 19147996
[TBL] [Abstract][Full Text] [Related]
15. Blood transfusion use in non-dialysis-dependent chronic kidney disease patients aged 65 years and older.
Ibrahim HN; Ishani A; Guo H; Gilbertson DT
Nephrol Dial Transplant; 2009 Oct; 24(10):3138-43. PubMed ID: 19451656
[TBL] [Abstract][Full Text] [Related]
16. Initiation of anaemia management in patients with chronic kidney disease not on dialysis in the Veterans Health Administration.
Lawler EV; Gagnon DR; Fink J; Seliger S; Fonda J; Do TP; Gaziano JM; Bradbury BD
Nephrol Dial Transplant; 2010 Jul; 25(7):2237-44. PubMed ID: 20083469
[TBL] [Abstract][Full Text] [Related]
17. Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations.
Duh MS; Mody SH; Scott McKenzie R; Lefebvre P; Gosselin A; Tak Piech C
Clin Ther; 2006 Sep; 28(9):1443-50. PubMed ID: 17062316
[TBL] [Abstract][Full Text] [Related]
18. Economic burden prior to COPD diagnosis: a matched case-control study in the United States.
Akazawa M; Halpern R; Riedel AA; Stanford RH; Dalal A; Blanchette CM
Respir Med; 2008 Dec; 102(12):1744-52. PubMed ID: 18760581
[TBL] [Abstract][Full Text] [Related]
19. Outcomes and costs of patients with persistent asthma treated with beclomethasone dipropionate hydrofluoroalkane or fluticasone propionate.
Lage MJ; Gross GN; Brewster C; Spalitto A
Adv Ther; 2009 Aug; 26(8):762-75. PubMed ID: 19669630
[TBL] [Abstract][Full Text] [Related]
20. Impact of pharmacist-managed erythropoiesis-stimulating agents clinics for patients with non-dialysis-dependent CKD.
Aspinall SL; Cunningham FE; Zhao X; Boresi JS; Tonnu-Mihara IQ; Smith KJ; Stone RA; Good CB;
Am J Kidney Dis; 2012 Sep; 60(3):371-9. PubMed ID: 22633556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
